

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI487441

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
AVENTIS PHARMA LIMITED	09/03/2024
RECEIVING PARTY DATA	
Company Name:	AUTO INJECTION TECHNOLOGIES LLC
Street Address:	104 East Houston Street Suite 140
City:	Marshall
State/Country:	TEXAS
Postal Code:	75670
PROPERTY NUMBERS Total: 2	
Property Type	Number
Patent Number:	8083127
Patent Number:	7322352
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	212-257-5797
Email:	ip@remotedocket.com
Correspondent Name:	FABRICANT LLP
Address Line 1:	230 Park Avenue, 3rd Floor W.
Address Line 4:	New York, NEW YORK 10169
ATTORNEY DOCKET NUMBER:	Auto Injector Technologie
NAME OF SUBMITTER:	Eddie Rowell
SIGNATURE:	Eddie Rowell
DATE SIGNED:	09/11/2024
Total Attachments: 3	
source=APL Assignment (part 1) - signed#page1.tiff	
source=APL Assignment (part 1) - signed#page2.tiff	
source=APL Assignment (part 1) - signed#page3.tiff	

PATENT ASSIGNMENT

This patent assignment (“**Assignment**”) is entered into as of September 3, 2024 (the “**Effective Date**”) by the between **AVENTIS PHARMA LIMITED (“APL”)**, a United Kingdom corporation having a principal place of business at 410 Thames Valley Park Drive, Reading, Berkshire, England, RG6 1PT (“**Assignor**”), and **AUTO INJECTION TECHNOLOGIES LLC**, a Texas-based entity having a principal place of business at 104 East Houston Street Suite 140 Marshall TX 75670 USA (“**Assignee**”), all of Assignor’s right, title, and interest in and to the following (collectively, the “**Assigned Patent Rights**”):

For good and valuable consideration, the receipt of which is hereby acknowledged, Assignor hereby irrevocably sell, assign, transfer, and convey to Assignee, as the Effective Date, all of the Assignor’s existing right, title and interest for the United States of America and its territorial possessions, and all foreign countries including all rights of priority, in inventions disclosed in:

- (a) the patents and patent applications and any terminally disclaimed to or from such patents (U.S. or Foreign) (the “**Patents**”) solely owned by Assignor and expressly identified on **Exhibit A**, together with;
- (b) future applications for patents under U.S. law or regulation or of any foreign country with respect to the patentable inventions filed by Assignee from which any of the foregoing arise, including without limitation, divisions, continuations, continuations-in-part, substitutions, reexaminations, reissues, extensions, continuing prosecution application, requests for continuing examinations, registrations of any of the Patents and foreign counterparts therefrom (collectively, “**Assigned Patents**”);
- (c) rights to apply in any or all countries of the world for future patents, certificates of invention, utility models, industrial design protections, design patent protections, or other future governmental grants or issuances of any type related to the Patents; and
- (d) all causes of action, enforcement rights, and remedies of any kind arising under any such Assigned Patent prior to, on or after the Effective Date of this Agreement and/or any of the items described in either of the foregoing categories (b) or (c) , including, without limitation, all causes of action, enforcement rights and all other rights to seek and obtain any other remedies of any kind for past, current, and future infringement and all claims for damages by reason of past, present or future infringement or other unauthorized use of such Assigned Patents with the right to sue for and collect such damages.

Assignor hereby authorizes the respective patent office or governmental agency in each jurisdiction to issue any and all future patents, certificates of invention, utility models or other governmental grants or issuances that may be granted upon any of the Assigned Patent Rights in the name of Assignee, as the assignee to the entire interest therein. This Assignment of Patent Rights will inure for the benefit of any permitted successors or assigns of Assignee.

Assignor will, at the reasonable request of Assignee, take all reasonable steps necessary and proper, to confirm the assignment to Assignee of the Assigned Patent Rights pursuant to this Assignment of Patent Rights, including without limitation, the execution, acknowledgment, and recordation of specific assignments, oaths, declarations, and other documents on a country-by-country basis, to assist Assignee in obtaining and perfecting the Assigned Patent Rights.

IN WITNESS WHEREOF, Assignor has caused its duly authorized representatives to execute this Assignment.

AVENTIS PHARMA LIMITED (“THE ASSIGNOR”)

By: *ripon*
ripon (Sep 3, 2024 19:41 GMT+1)

Name: rippon

Title: GM

Exhibit A

Patents

Publication Number	Family
US8083127B2	US7322352